• 동의생리병리학회지
• /
• 제17권2호
• /
• pp.403-411
• /
• 2003

For evaluating the effect of Siegesbeckiae Herba (here after abbreviated as SBH) on rheumatoid arthritis, the experiment was carried out; Incidence of rheumatoid arthritis, IRA(indices of rheumatoid arthritis), immunophenotypes by flow cytometer and histopathological changes in MRL/MpJ-Ipr-Ipr Mice in vivo were studied. The results were obtained as follows: 1. Incidence of RA in MRL/Ipr mice was suppressed to 60% of control by SBH. 2. IRA was significantly reduced for IgG3 and IgM at 20 weeks of age and for IgG2b at 12 and 20 weeks of age in mice by SBH compared with control. 3. Immunophenotypes such as CD4/sup +//CD25/sup +/, CD8/sup +//CD3e/sup +/, CD69/sup +//B220/sup +/, NK/sup +//CD3e/sup +/ were significantly increased by SBH compared with control. 4. In histopathological analysis, SBH suppressed the progression of PMN(polymorphonuciear leukocyte), leukocyte and fibroblast infiltration, and subsynovial soft tissue edema frequently showing in the early stage of the arthritis, and also effectively reduced the degeneration of cartilages and degenerative bone symptoms. These results suggest Siegesbeckiae Herba can be effectively applied to the treatment of rheumatoid arthritis and it is still necessary to isolate effective compound from Siegesbeckiae Herba in the near future.

• Biomolecules & Therapeutics
• /
• 제21권4호
• /
• pp.290-298
• /
• 2013

This study examined the effects of calcium (Ca) gluconate on collagen-induced DBA mouse rheumatoid arthritis (CIA). A single daily dose of 200, 100 or 50 mg/kg Ca gluconate was administered orally to male DBA/1J mice for 40 days after initial collagen immunization. To ascertain the effects administering the collagen booster, CIA-related features (including body weight, poly-arthritis, knee and paw thickness, and paw weight increase) were measured from histopathological changes in the spleen, left popliteal lymph node, third digit and the knee joint regions. CIA-related bone and cartilage damage improved significantly in the Ca gluconate-administered CIA mice. Additionally, myeloperoxidase (MPO) levels in the paw were reduced in Ca gluconate-treated CIA mice compared to CIA control groups. The level of malondialdehyde (MDA), an indicator of oxidative stress, decreased in a dose-dependent manner in the Ca gluconate group. Finally, the production of IL-6 and TNF-${\alpha}$, involved in rheumatoid arthritis pathogenesis, were suppressed by treatment with Ca gluconate. Taken together, these results suggest that Ca gluconate is a promising candidate anti-rheumatoid arthritis agent, exerting anti-inflammatory, anti-oxidative and immunomodulatory effects in CIA mice.

• 한방재활의학과학회지
• /
• 제19권2호
• /
• pp.89-102
• /
• 2009

Objectives : This study was carried out to understand the immunity responses and anti-oxidation effect of the Gamidaeganghwal-tang(GDT) on rheumatoid arthritis by using the THP-1 cells and the serum of CIA mice. Methods : For this purpose, GDT was orally administerd to mice with rheumatoid arthritis induced by collagen II. To investigate the immunity responses, value of cytokine and gene expression in the THP-1 cell, levels of cytokines in the serum of CIA(collagen type II induced arthritis) mice, number of immunocyte in PBMC of CIA mice were measured. Then, anti-oxidant activity, scavenging activity on DHHP(2,2-diphenyl-1-picrylhydrazyl) free radical and SOD(Superoxide dismutae)-like activity of GDT was observed. Results : 1. The levels of IL-$1{\beta}$, IL-6, IL-8, MCP-1 at 100, $50{\mu}g/m{\ell}$ of GDT were significantly reduced in the THP-1 cell. 2. The levels of TNF-${\alpha}$, COX-2 mRNA expression at 100, $50{\mu}g/m{\ell}$ of GDT and IL-$1{\beta}$, IL-6 at $100{\mu}g/m{\ell}$ of GDT were significantly reduced in the THP-1 cell line. 3. The levels of IL-6, TNF-${\alpha}$ and IL-$1{\beta}$ were significantly reduced in the serum of CIA mice. 4. The absolute number of CD3+, CD4+ and CD8+ cells were significantly induced, CD3+/CD69+, CD3+/CD49+, CD19+, B220+/CD23+ cells were significantly reduced in PBMC. 5. Scavenging activity on DPPH free radical and SOD-like activity were significantly induced in a concentration dependent manner. Conclusions : Taking all these observations, GDT considered to be effective in treating rheumatoid arthritis. Therefore we have to survey continuously in looking for the effective substance and mechanism in the future.

• 한국응용과학기술학회지
• /
• 제39권1호
• /
• pp.18-26
• /
• 2022

본 연구는 CIA에 의해 유발된 DBA/1 마우스를 통해 류마티스관절염 바이오마커에 대한 두충 추출물의 효과를 평가하였다. 평가를 위해 류마티스관절염 동물모델 제작 후 100 mg/kg/day로 4주간 경구 투여하고 혈청 바이오마커, 방사선, 구조적 매개변수 분석을 통해 치료 효과를 확인하였다. 음성대조군과 비교하여, 두충 추출물은 염증 및 면역글로불린 마커(TNF-α, IgG 및 hs-CRP)의 생성을 유의하게 감소시켰고, 백혈구의 단핵구 수를 유의적으로 감소시켰다. 또한, 두충 추출물은 관절 파괴를 효과적으로 보존하고 관절 변형을 줄였으며, 골 밀도의 증가와 유의적으로 골 염증을 감소시켰다. 이러한 결과는 두충 추출물이 류마티스관절염 증상을 개선하는 것을 나타낸다. 따라서, 두충 추출물은 류마티스관절염 관리를 위한 새로운 치료 옵션이 될 수 있음을 보여준다.

• 임상간호연구
• /
• 제16권2호
• /
• pp.107-116
• /
• 2010

Purpose: The purpose of this study was to examine the effects of a self-management program on self-efficacy and quality of life for Korean women with rheumatoid arthritis. Methods: A quasi-experimental study using a nonequivalent control group pretest posttest design was used. The data were collected from July 1 to Sep. 15, 2007. Thirty one arthritis patients (15 in the experimental group and 16 in the control group) were participated in this study. A self-management program developed by Korean Society of Muscle and Joint Health in 1994 was used. The program was consisted of 6 sessions, 2 hours each and held every Friday for 6 weeks. General Self-Efficacy Scale and Quality of Life were used to test the effect of the program. Results: Hypothesis 1; "Self-efficacy in the experimental group after program would be higher than the control group" was supported. Hypothesis 2; "Quality of Life in the experimental group after program would be higher than the control group " was not supported. Conclusion: The self-management program was effective for Korean women with rheumatoid arthritis in terms of increasing self-efficacy. Therefore, to increase self-management skills and self-efficacy for female rheumatoid arthritis patients, the program can be useful.

• Clinics in Shoulder and Elbow
• /
• 제1권1호
• /
• pp.12-18
• /
• 1998

To purpose of this study was to evaluate clinical results between rheumatoid arthritis shoulder cases and traumatic proximal humerus fracture cases. Fourteen patients who had been shoulder hemiarthroplasties between March 1991 to July 1996, six had rheumatoid arthritis and eight had comminuted proximal humerus fracture by the various trauma. Neer II prothesis were implanted in twenty cases and global prothesis were implanted in two cases. The follow up period was 15 months to 36 months. To evaluate this study, we used the UCLA shoulder rating. We were able to follow up thirteen cases for more than fifteen months, of which five cases had excellent, five cases had good, two cases had fair and one case had poor. And the results were better for patients with rheumaroid arthritis than for patients with trauma.

• Journal of Acupuncture Research
• /
• 제19권5호
• /
• pp.189-198
• /
• 2002

Objective : To research the trend of the study related to rheumatoid arthritis(RA) and to establish the hereafter direction of the study on RA. Methods : We have selected 12 medical report about RA in Arthritis & Rheumatism and Journal of Rheumatology recently, reviewed them, and investigated their methods. Results & Conclusions : The pattern of study was as follows: physical & serologic research in 2 articles, immunologic research in 7 articles, and genetic research in 3 articles. There is now evidence of the benefit of treatment early in the disease course and evidence of the impact of treatment on outcomes. New classes of therapeutic agents have also been introduced. Wherever possible, these revised guidelines are evidence-based. By the above results, it would be needed further research on RA mechanism related immunologic and genetic process.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2001년도 추계학술대회 및 정기총회
• /
• pp.41-76
• /
• 2001

Rheumatoid arthritis is an incurable chronic inflammatory and destructive arthopathy that affects 1% of the population world-wide. It has substantial personal, social and economic costs. The long-term prognosis is poor: 80 percent of affected patients will become disabled within 20 years after onset of disease. Medical costs of rheumatoid arthritis average ∼$ 6000 (US) per patient (1), Current antirheumatic drugs have limited efficacy and many side effects and more importantly they do not improve the long-term prognosis of rheumatoid arthritis (2). After a decade of few notable advances in therapy, several biological response modifiers that target pathophysiological processes in the disease have now emerged in the clinic. These new drugs are termed biological agents, and although information about their use in the clinic is still limited to short term treatment, they appear to have the ability to modify disease progress. In addition, COX-2 selective agents have now been approved that have comparable efficacy with standard NSAIDs, but fewer gastrointestinal side effects (3). Thus today many more therapeutic options are suddenly open to patients that even five years ago had little hope of relief from chronic pain and inflammation.

• 혜화의학회지
• /
• 제11권1호
• /
• pp.217-235
• /
• 2002

NSAIDs(Non-steroidal anti-inflammatory drug), Steroid(corticosteroid), DMARD(Dise modifying anti-rheumatic drug), Immunosuppressive agent, BRM(Biologic response modifier) western medication of Rheumatoid arthritis. Recent trends in western medication of Rheum arthritis is an inverted pyramid treatment. Byunjeungsichi(辨證施治), Yakchim(藥針), Oechibub(外治法 external treatment) are orie medication of Rheumatoid arthritis. Yakchim(藥針) and Oechibub(外治法 external treatment) the advantage of trouble in oral administration.

• IMMUNE NETWORK
• /
• 제16권1호
• /
• pp.44-51
• /
• 2016

Dendritic cells (DCs) are professional antigen presenting cells, and play an important role in the induction of antigen-specific adaptive immunity. However, some DC populations are involved in immune regulation and immune tolerance. These DC populations are believed to take part in the control of immune exaggeration and immune disorder, and maintain immune homeostasis in the body. Tolerogenic DCs (tolDCs) can be generated in vitro by genetic or pharmacological modification or by controlling the maturation stages of cytokine-derived DCs. These tolDCs have been investigated for the treatment of rheumatoid arthritis (RA) in experimental animal models. In the last decade, several in vitro and in vivo approaches have been translated into clinical trials. As of 2015, three tolDC trials for RA are on the list of ClinicalTrial.gov (www.clinicaltrials.gov). Other trials for RA are in progress and will be listed soon. In this review, we discuss the evolution of tolDC-based immunotherapy for RA and its limitations and future prospects.